Key result
High Lp-PLA2 levels (>138 nmol/L) were associated with an increased risk of all-cause mortality and rehospitalization in Chinese patients with ACS undergoing PCI (HR 1.429; 95% CI 1.411-1.448; P<.05).
Why the study?
Does high Lp-PLA2 predict all-cause mortality and rehospitalization in Chinese patients with ACS undergoing PCI?
Cohort (n=651)
Does high Lp-PLA2 predict all-cause mortality and rehospitalization in Chinese patients with ACS undergoing PCI?
Hazard Ratio: 1.429 (95% CI 1.411–1.448)
p-value: p=< .05
High Lp-PLA2 levels (>138 nmol/L) independently predict long-term all-cause mortality and rehospitalization in Chinese patients with ACS undergoing PCI.
Elevated Lp-PLA2 may refine post-PCI risk stratification in ACS; leaves open whether it is a modifiable target.
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an independent risk factor for cardiovascular disease. Accordingly, studies from many countries around the world have shown an association between Lp-PLA 2 and cardiovascular events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), but this association has not been documented among the Chinese. The aim of this study was to assess the use of Lp-PLA 2 as a useful marker for predicting the long-term prognosis of Chinese patients with ACS undergoing PCI. A total of 651 consecutive patients undergoing PCI between September 2013 and January 2015 were divided into 2 groups: the high Lp-PLA 2 group (n = 262, Lp-PLA 2 > 138 nmol/L) and the low Lp-PLA 2 group (n = 389, Lp-PLA 2 ≤ 138 nmol/L). The end point was all-cause mortality and rehospitalization. The median follow-up was 24 months. Multivariate analysis showed that high Lp-PLA 2 was an independent predictor of all-cause mortality and rehospitalization (hazard ratio: 1.429, 95% confidence interval [CI]: 1.411-1.448; P < .05). The Lp-PLA 2 had good accuracy for predicting all-cause mortality and rehospitalization among patients with ACS undergoing PCI (area under the receiver–operating characteristic curve: 0.858, 95% CI: 0.819-0.898; P < .05), and a good correlation with the Global Registry of Acute Coronary Event score ( r = 0.525, P < .05). This study provided evidence that Lp-PLA 2 could predict all-cause mortality and rehospitalization risk among patients with ACS undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2017) conducted a cohort in Acute coronary syndrome undergoing percutaneous coronary intervention (n=651). High Lp-PLA2 (> 138 nmol/L) vs. Low Lp-PLA2 (≤ 138 nmol/L) was evaluated on all-cause mortality and rehospitalization (HR 1.429, 95% CI 1.411-1.448, p=< .05). High Lp-PLA2 levels (>138 nmol/L) were associated with an increased risk of all-cause mortality and rehospitalization in Chinese patients with ACS undergoing PCI (HR 1.429; 95% CI 1.411-1.448; P<.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: